Free Newsletter
Biomedical researchers lobby against funding cuts
Some of the country's top biomedical researchers have been beating a path to Congress in an attempt to fend off deep cuts in research funds. Nobel Prize winner Roger D. Kornberg, for example, has been making the point that it was doubtful he could have done his groundbreaking work on the way DNA is copied in the current budgetary environment. "In the present climate especially, the funding decisions are ultraconservative," he told The Washington Post. "If the work that you propose to do isn't virtually certain of success, then it won't be funded." As a result, young scientists are steering away from research and big leaps promised in cancer, Alzheimer's and other diseases may never materialize.
- check out the UPI report on the protests
Related Article:
Institutions lament squeeze on federal research funds. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




